Klinische Wirksamkeit und Verträglichkeit von Zonisamid

Zusammenfassung

Mit Zonisamid (Zonegran®) steht nun in Europa seit 2005 ein innovatives Antiepileptikum zur Verfügung, das sich durch ein gutes Verhältnis von Wirksamkeit zu Verträglichkeit auszeichnet. Neben dem günstigen pharmakokinetischen Profil machen es vor allem die multiplen Wirkmechanismen und das geringe Interaktionspotenzial zu einem geeigneten Partner in der Kombinationstherapie der Epilepsie. Die klinische Wirksamkeit und Verträglichkeit wurde in vier doppelblinden, plazebokontrollierten Zusatztherapiestudien an insgesamt 845 refraktären, erwachsenen Patienten mit bis zu neunmonatiger Dauer belegt. Die darin erzielten globalen Responderraten von bis über 50 % sprechen für eine hohe Wirksamkeit bei fokalen Anfällen mit und ohne sekundäre Generalisierung.

Abstract

Since 2005 Zonisamide is available in Europe as an innovative antiepileptic drug with a good efficacy vs. tolerability-ratio. Because of a favourable pharmacokinetic profile, multiple mechanisms of actions and a low interaction potential zonisamide is ideal for combination therapy of partial epilepsies. Clinical efficacy and tolerability was demonstrated by four double-blind placebo-controlled add-on-studies in 845 adult patients with refractory partial epilepsies with a follow-up of up to nine month maximum. Responder rates of seizure-reduction up to more than 50 % indicate high clinical efficacy in patients with partial seizures with and without secondary generalization.

Literatur

• 1 Suzuki S, Kawakami K, Nishimura S. et al . Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex.  Epilepsy Res. 1992;  12 21-27
• 2 Schauf C L. Zonisamide enhances slow sodium inactivation in Myxicola.  Brain Res. 1987;  413 185-188
• 3 Okada M, Kawata Y, Mizuno K. et al . Interaction between Ca²⁺, K⁺, carbamazepine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode.  Br J Pharmacol. 1998;  124 1277-1285
• 4 Zhu W J, Rogawski M A. Zonisamide depresses excitatory synaptic transmission by a presynaptic action.  Epilepsia. 1999;  40 (Suppl 7) 245
• 5 Kawai M, Hiramatsu M, Endo A. et al . Effect of zonisamide on release of aspartic acid and gamma-aminobutyric acid from hippocampal slices of E1 mice.  Neurosciences. 1994;  20 115-119
• 6 MacDonald R L. Zonisamide: mechanism of action. In: Levy RH (ed) Antiepileptic Drugs, 5^th ed. Philadelphia; Lippincott, Williams & Wilkins 2002: 867-872
• 7 Brodie M J, Duncan R, Vespignani H. et al . Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures.  Epilepsia. 2005;  46 31-41
• 8 Faught E, Ayala R, Montouris G. et al . Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures.  Neurology. 2001;  57 1774-1779
• 9 Sackellares J C, Ramsay R E, Wilder B J. et al . Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures.  Epilepsia. 2004;  45 610-617
• 10 Schmidt D, Jacob R, Loiseau P. et al . Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial.  Epilepsy Res. 1993;  15 67-73
• 11 Hirsch E, Duncan R. Zonisamide improves seizure control in a dose-dependent manner in patients with refractory partial epilepsy.  Eur Neurol. 2005;  45 (Suppl 2) 15
• 12 Chadwick D W, Marson A G. Zonisamide add-on for drug-resistant partial epilepsy. The Cochrane Database of Systematic Reviews 2005 Issue 4, Art. 16: CD001416.pub2 DOI: 10.1002/14651858.CD001416.pub2
• 13 Mayer T, Silver G, Remy C. et al .Efficacy and safety of zonisamide as an adjunctive therapy for partial epilepsy uncontrolled with one antiepileptic drug. Posterpräsentation, 15^th Annual Meeting of the European Neurological Society (ENS). Wien; 2005
• 14 Alapati A, Hall-Bell C, Faught E R. Safety and efficacy of zonisamide adjunctive therapy for refractory complex partial seizures: an open label study.  Epilepsia. 2000;  41 (Suppl 7) 225
• 15 French J A, Ruelle A D. Zonisamide reduces seizure frequency over time in long-term continuation studies.  Epilepsia. 2002;  43 (Suppl 7) 241
• 16 French J A. Determination of long-term response to zonisamide therapy in patients with epilepsy. Manuscript submitted. 
• 17 Brodie M J. Zonisamide clinical trials: European experience.  Seizure. 2004;  13 (Suppl 1) 66-70
• 18 Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures.  Seizure. 2004;  13 (Suppl 1) 59-65
• 19 Wroe S, Brodie M J. Zonisamide maintains or improves seizure control and is well tolerated over 2 years in patients with refractory partial epilepsy: interim analysis of an open-label extension study.  Eur Neurol. 2005;  252 (Suppl 2) 14
• 20 Tosches W A, Tisdell J. Efficacy and safety of long-term zonisamide monotherapy and adjunctive therapy.  Epilepsia. 2005 a;  46 (Suppl 6) 143
• 21 French J A, Ruelle A D. Long-term use of Zonisamide.  Platform Presentations. 2003;  3 694
• 22 French J A. Long-term Zonisamide therapy does not cause tachyphylaxis. Posterpräsentation. Washington; 59th Annual Meeting of the American Epilepsy Society 2005
• 23 Seino M, Ohkuma T, Miyasaka M. et al . Efficacy evaluation of AD-810 (zonisamide). Results of a double blind comparison with carbamazepine.  J Clin Exp Med. 1998;  144 275-291
• 24 Marmarou A, Pellock J M. Zonisamide: Physician and patient experiences.  Epilepsy Res. 2005;  64 63-69
• 25 Fachinformation Zonegran®, Stand März 2007, Eisai Ltd. 
• 26 Brodie M J. Zonisamide as adjunctive therapy for refractory partial seizures.  Epilepsy Res. 2006;  68 (Suppl 2) 11-16
• 27 Yagi K, Seino M. Methodological requirements for clinical trials in refractory epilepsies - our experience with zonisamide.  Prog Neuro Psychopharmacol Biol Psychiatr. 1992;  16 79-85
• 28 Lee B I. Zonisamide: adverse effects. In: Levy R, Mattson R, Meldrim B, Perucca E (eds) Antiepileptic Drugs, 5^th ed. Philadelphia; Lippincott, Williams & Wilkins Healthcare 2002: 96-102
• 29 Leppik I E, Willmore L J, Homan R W. et al . Efficacy and safety of zonisamide: results of a multicenter study.  Epilepsy Res. 1993;  14 165-173
• 30 Welty T E, Kuzniecky R I, Limdi N. et al . Weight loss associated with use of Zonisamide in Europe and United States clinical trials.  Epilepsia. 2001;  42, Suppl 7 262
• 31 Biton V. Effect of antiepileptic drugs on bodyweight.  CNS Drugs. 2003;  17 781-791
• 32 Svenson C K, Cowen E W, Gaspari A A. Cutaneous drug reaction.  Pharmacol Rev. 2001;  53 357-379
• 33 Reilly T P, Ju C. Mechanistic perspectives on sulfonamide-induced cutaneous drug reactions.  Curr Allergy Clin Immunol. 2002;  2 307-315
• 34 Frampton J E, Scott L J. Zonisamide: A Review of its use in the management of partial seizures in epilepsy.  CNS Drugs. 2005;  19 347-368
• 35 Leppik I E. Practical prescribing and long-term efficacy and safety of zonisamide.  Epilepsy Res. 2006;  68, Suppl 2 17-24